We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Danaher Corporation | NYSE:DHR | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.27 | 0.11% | 246.89 | 249.52 | 244.55 | 246.26 | 2,310,442 | 01:00:00 |
From May 2019 to May 2024
By Stephen Nakrosis
The U.S. Federal Trade Commission on Thursday said Danaher Corp. has agreed to divest some assets as a condition to its proposed acquisition of GE Biopharma.
The FTC said the $21.4 billion deal would violate U.S. antitrust laws by lessening competition "in highly concentrated product markets for 10 products that companies use to manufacture biopharmaceutical drugs."
Under the terms of the deal, the FTC said, Danaher will "divest all rights and assets to research, develop, manufacture, market, and sell these products" to Germany's Sartorius AG.
In February of last year, General Electric Co. said it would sell the GE Biopharma business to Danaher.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 19, 2020 18:41 ET (22:41 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Danaher Chart |
1 Month Danaher Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
